Business
SBTX signs MTA with global consumer goods company
SBTX signs MTA with global consumer goods company.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 4957J SkinBioTherapeutics PLC 03 April 2018 \n\nSkinBioTherapeutics plc\n \nSkinBioTherapeutics signs MTA (material transfer agreement) with global consumer goods company\n \nManchester, UK - 03 April 2018 - SkinBioTherapeutics plc (AIM: SBTX, the \"Company\"), a life science company focused on skin health, announces the signing of an MTA relating to its proprietary SkinBiotix® technology with a major, global consumer goods company.\nThe Company has been speaking to a range of commercial partners interested in evaluating its SkinBiotix® technology ahead of its human studies which are scheduled to commence later this year. \nHaving shared the initial pre-clinical data with a number of interested parties, one potential partner to date has progressed to an MTA, granting it access to the SkinBiotix® technology. An MTA is a standard agreement governing the transfer of material between parties enabling the recipient to assess the technology and, where the outcome is successful, can be a precursor to future commercial discussions. \nThe MTA provides for SkinBioTherapeutics to share a sample of its material against which the third party will conduct its own in-house assessment. Whilst at this stage there can be no certainty that discussions will progress further than the initial sharing of the technology, the Company is encouraged by the level of interest that has been shown in its pre-clinical data. \nThe Company is initially targeting cosmetic skin care and in this market SkinBioTherapeutics' skin microbiome technology is unusual in that its properties are supported by scientific data. These demonstrate its ability to improve the skin barrier, offer protection from infection and enhance skin repair. These characteristics support potential opportunities for the Company in cosmetics, anti-infectives and dermatological indications (e.g. eczema). \n \nMost recently, the Company reported good results in a variety of toxicity studies and the development of its formulation as a gel, cream and lotion which will be tested to determine the best concentration and application for its humans studies. \n \nDr Cath O'Neill, CEO of SkinBioTherapeutics, commented:\n\"Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely t...